RxDoctor Payments Data

la Tanya Lawrence

Family · Saint Louis, MONPI 1104121102

Payments from drug & device makers

$1,327in general payments, 2019–2025

Across 38 payments — averaging $34.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$414
  • AstraZeneca$381
  • Novo Nordisk$299
  • AbbVie$111
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$81
  • Exact Sciences$25
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$1,327100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,327 in reported general payments places this provider in the 70th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$332
Medicare patients
13
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase15$37,530
JardianceEmpagliflozin43$35,719
TrulicityDulaglutide24$27,490
OzempicSemaglutide27$27,065
EliquisApixaban19$18,570
XareltoRivaroxaban22$16,619
FarxigaDapagliflozin Propanediol13$14,741
MounjaroTirzepatide13$14,284
Albuterol Sulfate HfaAlbuterol Sulfate153$3,566
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate26$2,986
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$2,564
SymbicortBudesonide/Formoterol Fumarate12$2,505
Advair DiskusFluticasone Propion/Salmeterol12$2,292
Gabapentin110$2,248
Omega-3 Acid Ethyl Esters11$1,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$414$41,77437 claims
AbbVieCreon$111$37,53015 claims
Novo NordiskOzempic$299$27,06527 claims
AstraZenecaFarxiga, Symbicort$381$17,24725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,812 family providers in Missouri.

Other family in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →